🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against superbug strains of the pathogen, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating globally, with data suggesting over 82 million new cases per year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The study involved hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Doctors directly involved have voiced optimism. Having a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is considered essential to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea around the world.